The paper, titled BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells, will be published in the "Our work demonstrates that there are fundamental differences between the metabolism of leukemia stem cells compared to the mass of tumor and normal cells.
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Seahorse-Bioscience-XF-Technology-Yields-Insights-/ArticleNewsFeed/Article/detail/806408?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Seahorse-Bioscience-XF-Technology-Yields-Insights-/ArticleNewsFeed/Article/detail/806408?ref=25
No comments:
Post a Comment